Keywani, Kammy http://orcid.org/0000-0002-4027-8715
Borgstein, Alexander B. J.
Eshuis, Wietse J.
Pape, Marieke
Versteeg, Kathelijn S.
Derks, Sarah
van Laarhoven, Hanneke W. M.
Gisbertz, Suzanne S.
Verhoeven, Rob H. A.
van Berge Henegouwen, Mark I.
Article History
Received: 27 March 2023
Accepted: 25 May 2023
First Online: 7 June 2023
Declarations
:
: Prof. Dr. van Laarhoven reported being honorary chair upper GI faculty of European Society for Medical Oncology; serving in a consulting or advisory role for Amphera, Astellas, AstraZeneca, Beigene, BMS, Daiichy-Sankyo, Dragonfly, MSD, Novartis, and Servier; receiving research grants and nonfinancial support from Bayer, BMS, Celgene, Janssen, Incyte, Philips, Roche, and Servier; serving as speaker for Astellas, Benecke, Daiichy-Sankyo, JAAP, Medtalks, Novartis, and Travel Congress Management B.V. outside the submitted work. Dr. Verhoeven reported serving in a consulting or advisory role for Daiichi Sankyo; receiving research grant from Bristol Myers Squibb outside the submitted work. Prof. Dr. van Berge Henegouwen reported serving in a consulting or advisory role for Alesi Surgical, BBraun, Johnson and Johnson, Medtronic, and Viatris; receiving research grants from Stryker outside the submitted work. The remaining authors declare that they have no conflict of interest.